Prognostic value of plasma β-amyloid levels in patients with acute intracerebral hemorrhage

Stroke

Volumn 45, Issue 2, 2014, Pages 413-417

  Martí Fàbregas, Joan ^a   Delgado Mederos, Raquel ^a   Marín, Rebeca ^a   De La Ossa, Natalia Pérez ^b   De Leciñana, María Alonso ^c   Rodríguez Yáñez, Manuel ^d   Sanahuja, Jordi ^e   Purroy, Francisco ^e   De Arce, Ana María ^f   Carrera, David ^a   Dinia, Lavinia ^a   Guardia Laguarta, Cristina ^a   Lleó, Alberto ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^e HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^f HOSPITAL DONOSTIA   (Spain)

Author keywords

Amyloid; Cerebral hemorrhage; Prognosis

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; GLUCOSE;

ACUTE DISEASE; AGE; AGE DISTRIBUTION; AGED; ARTICLE; BRAIN HEMATOMA; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FUNCTIONAL ASSESSMENT; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROGNOSTIC VALUE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANKIN SCALE; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX; SEX DIFFERENCE;

AMYLOID; CEREBRAL HEMORRHAGE; PROGNOSIS;

AGE FACTORS; AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; CEREBRAL HEMORRHAGE; CONFIDENCE INTERVALS; DATA INTERPRETATION, STATISTICAL; DIABETES COMPLICATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; PEPTIDE FRAGMENTS; PROGNOSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SEX FACTORS; TREATMENT OUTCOME;

EID: 84893682227     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.002838     Document Type: Article

References (34)

1. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9:167-176.
2. Hemphill JC III, Bonovich DC, Besmertis L, Manley GT, Johnston SC. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke. 2001;32:891-897.
3. Rost NS, Smith EE, Chang Y, Snider RW, Chanderraj R, Schwab K, et al. Prediction of functional outcome in patients with primary intracerebral hemorrhage: the FUNC score. Stroke. 2008;39:2304-2309.
4. Leira R, Dávalos A, Silva Y, Gil-Peralta A, Tejada J, Garcia M, et al; Stroke Project, Cerebrovascular Diseases Group of the Spanish Neurological Society. Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors. Neurology. 2004;63:461-467.
5. Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, et al; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66:1175-1181.
6. Charidimou A, Gang Q, Werring DJ. Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry. 2012;83:124-137.
7. Aguilar MI, Freeman WD. Spontaneous intracerebral hemorrhage. Semin Neurol. 2010;30:555-564.
8. Revesz T, Holton JL, Lashley T, Plant G, Rostagno A, Ghiso J, et al. Sporadic and familial cerebral amyloid angiopathies. Brain Pathol. 2002;12:343-357.
9. Auriel E, Greenberg SM. The pathophysiology and clinical presentation of cerebral amyloid angiopathy. Curr Atheroscler Rep. 2012;14:343-350.
10. Attems J, Lauda F, Jellinger KA. Unexpectedly low prevalence of intracerebral hemorrhages in sporadic cerebral amyloid angiopathy: an autopsy study. J Neurol. 2008;255:70-76.
11. Smith EE, Greenberg SM. Beta-amyloid, blood vessels, and brain function. Stroke. 2009;40:2601-2606.
12. Lee PH, Bang OY, Hwang EM, Lee JS, Joo US, Mook-Jung I, et al. Circulating beta amyloid protein is elevated in patients with acute ischemic stroke. J Neural Transm. 2005;112:1371-1379.
13. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology. 2001;56:537-539.
14. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC. Age but not diagnosis is the main predictor of plasma amyloid beta- protein levels. Arch Neurol. 2003;60:958-964.
15. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362:329-344.
16. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun. 1995;213:96-103.
17. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002;295:2264-2267.
18. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE mediates amyloid-beta peptide transport across the blood- brain barrier and accumulation in brain. Nat Med. 2003;9:907-913.
19. Keep RF, Hua Y, Xi G. Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. Lancet Neurol. 2012;11:720-731.
20. Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol. 2006;5:53-63.
21. van Dijk EJ, Prins ND, Vermeer SE, Hofman A, van Duijn CM, Koudstaal PJ, et al. Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol. 2004;55:570-575.
22. Gurol ME, Irizarry MC, Smith EE, Raju S, Diaz-Arrastia R, Bottiglieri T, et al. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology. 2006;66:23-29.
23. Gomis M, Sobrino T, Ois A, Millán M, Rodríguez-Campello A, Pérez de la Ossa N, et al. Plasma beta-amyloid 1-40 is associated with the diffuse small vessel disease subtype. Stroke. 2009;40:3197-3201.
24. Hernandez-Guillamon M, Delgado P, Penalba A, Rodriguez-Luna D, Molina CA, Rovira A, et al. Plasma β-amyloid levels in cerebral amyloid angiopathy-associated hemorrhagic stroke. Neurodegener Dis. 2012;10:320-323.
25. Greenberg SM, Cho HS, O'Donnell HC, Rosand J, Segal AZ, Younkin LH, et al. Plasma beta-amyloid peptide, transforming growth factor- beta 1, and risk for cerebral amyloid angiopathy. Ann N Y Acad Sci. 2000;903:144-149.
26. Verbeek MM, Kremer BP, Rikkert MO, Van Domburg PH, Skehan ME, Greenberg SM. Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy. Ann Neurol. 2009;66:245-249.
27. Herweh C, Prager E, Sykora M, Bendszus M. Cerebral atrophy is an independent risk factor for unfavorable outcome after spontaneous supratentorial intracerebral hemorrhage. Stroke. 2013;44:968-971.
28. Brouwers HB, Biffi A, Ayres AM, Schwab K, Cortellini L, Romero JM, et al. Apolipoprotein E genotype predicts hematoma expansion in lobar intracerebral hemorrhage. Stroke. 2012;43:1490-1495.
29. McCarron MO, Nicoll JA. Cerebral amyloid angiopathy and thrombolysis- related intracerebral haemorrhage. Lancet Neurol. 2004;3:484-492.
30. Dumas A, Dierksen GA, Gurol ME, Halpin A, Martinez-Ramirez S, Schwab K, et al. Functional magnetic resonance imaging detection of vascular reactivity in cerebral amyloid angiopathy. Ann Neurol. 2012;72:76-81.
31. Hardy J, Cullen K. Amyloid at the blood vessel wall. Nat Med. 2006;12:756-757.
32. Hong-Qi Y, Zhi-Kun S, Sheng-Di C. Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Abeta and tau. Transl Neurodegener. 2012;1:21-9158-1-21.
33. Xu F, Davis J, Miao J, Previti ML, Romanov G, Ziegler K, et al. Protease nexin-2/amyloid beta-protein precursor limits cerebral thrombosis. Proc Natl Acad Sci USA. 2005;102:18135-18140.
34. Huang Y, Potter R, Sigurdson W, Kasten T, Connors R, Morris JC, et al. β-Amyloid Dynamics in Human Plasma. Arch Neurol. 2012;69:1591-1597.